Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Third quarter results 2020: Strong results, increased order backlog

28 October 2020 – In an international market with corona-related volatilities, Kvaerner increased EBITDA -results, order intake and backlog during the third quarter, compared to the same period last year. Simultaneously, the company strengthened its financial platform. A positive cashflow increased the cash and bank deposits to NOK 2 029 million at the end of the quarter.In the last quarter, Kvaerner’s total revenues, including jointly controlled entities (Field Development segment) were NOK 1 836, compared to NOK 2 571 in the third quarter 2019. With a corresponding quarterly EBITDA result

Nordic Paper Interim report January – September 2020

Quarterly results july - September ·Net sales decreased by 19% to SEK 639m (791), excluding currency effects the decrease was 16% ·EBITDA was SEK -13m (153), corresponding to an EBITDA margin of -2.0% (19.4) ·Maintenance stop in Bäckhammar affected the result negatively by MSEK 79 (0). Corresponding costin 2019 of SEK 57m charged the fourth quarter. ·IPO costs in the quarter was SEK 10m (0) ·Operating result was SEK -40m (129), corresponding to an operating margin of -6.3% (16.3) ·Net result for the period amounted to SEK -32m (102) ·Cash

Targovax announces formation of new Scientific Advisory Board

Oslo, Norway, 28 October 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces the formation of a new Scientific Advisory Board (SAB). The SAB consists of a group of world-renowned experts in immuno-oncology research and drug development carefully selected to act as advisors to guide the Targovax R&D strategy.Victor Levitsky, Chief Scientific Officer of Targovax said: We are very pleased to have attracted such high caliber individuals with deep expertise in immuno-oncology to serve on the

Axactor reports Q3 financials

Oslo, October 28, 2020: Axactor’s financials for the third quarter 2020 saw a normalization in both revenue and earnings compared to the second quarter 2020. After the Covid-19 induced lockdowns across Europe earlier this year, early signs of recovery were visible towards the end of the second quarter. The positive trend has continued in the third quarter within all business segments. The REO segment did particularly well, with both volume and prices developing above expectations. Due to the prompt recovery, a net amount of EUR 5.1 million in impairment accruals was released. - The

CFO Survey: Swedish CFOs more positive despite considerable uncertainty

The financial outlook is showing a significant improvement since this past spring, and even though optimism about future business opportunities is lower than during last autumn’s survey, it is considerably higher than when it hit a low point during the spring. External uncertainty has risen to its highest level in four years, and it’s hardly surprising that companies’ top priority is to continue cutting costs.The CFO Survey is conducted twice a year and aims to highlight changes in sentiment among Swedish CFOs and compare these with the trend in the rest of Europe. This past spring we

Bio-Works signs agreement with BioInno Biosciences Co, Ltd to co-develop Asian markets and provide application and technical support

Bio-Works Technologies (Nasdaq First North) has signed a Supply and Reference Customer Agreement with the Jiangsu province-headquartered BioInno Bioscience Co., Ltd. The agreement covers development of the mainland Chinese and Asian markets by jointly providing technical expertise in downstream processing application development that showcases product benefits.Bio-Works is deepening its commitments in China and across Asia, by entering a second Supply and Reference Customer agreement with a local CDMO, BioInno Bioscience Co Ltd, located in the outskirts of Suzhou, Jiangsu province. By

Softwood log exports from Russia have been in steady decline for the past 15 years and may be banned in 2022

In a recent statement, the Russian President Mr. Putin ordered the government to strictly control the exportation of roundwood and low-value forest products, and to clamp down on the illegal trade of logs (in his terms: “hard-hitting decriminalization of the industry”). He also requested a “complete ban on shipments of unprocessed or roughly processed conifer and valuable hardwood out of Russia by January 1, 2022.” This statement would indicate that lower-value hardwood logs, such as birch pulplogs exported to Finland, may be excluded from the future export ban. To encourage domestic

Zwipe AS: Results of the Subsequent Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. OSLO, NORWAY – 27 October 2020 –  (Oslo, 27 October 2020) Reference is made to the stock exchange announcement from Zwipe AS ("Zwipe" or the "Company") dated 20 October 2020 relating to the subsequent offering and listing of up to  one million new shares in the Company, each with a nominal value of NOK 0.10 (the "Offer Shares"), at a subscription price of

Hexagon announces proposed dividend of 0.62 EUR per share

Hexagon AB’s Board of Directors proposes a dividend of 0.62 EUR per share for the fiscal year 2019. The proposal will be addressed at an Extraordinary General Meeting on 1 December 2020.During the spring, the Board of Directors withdrew its original dividend proposal of 0.62 EUR per share due to the uncertainty surrounding the COVID-19 pandemic. The Board of Directors has since then assessed the impact of the pandemic on the Company’s financial performance and has decided to reinstate the dividend proposal.  Due to the current circumstances, the Extraordinary General Meeting on 1

Enviro expects final partnership agreement with Michelin during the fourth quarter

Scandinavian Enviro Systems (publ) and the French global tyre manufacturer Michelin assess that a final agreement regarding a strategic partnership is expected to be reached during the fourth quarter 2020 instead of before the end of October, which Enviro has previously communicated. The reason for the delay is the ongoing pandemic which has led to protracted negotiations.N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail. Apart from the fact that the

Everfuel set to start trading on Merkur Market on 29 October under ticker EFUEL-ME

Oslo Børs today announced it has received Everfuel A/S’ application for admission to trading on Merkur Market and that the Listing Committee has decided to admit the company to trading. It is stipulated that the company prior to the first day of trading must satisfy the admission requirements on Merkur Market. The first trading date on Oslo Stock Exchange’s Merkur Market is expected to take place on 29 October 2020 under the ticker code EFUEL-ME and ISIN DK0061414711.    Click here for Oslo Børs statement .    For more information,

Arctic Paper S.A. extends revolving credit facility

Arctic Paper S.A. has agreed with lenders BNP Paribas Bank Polska S.A., Santander Bank Polska S.A. and European Bank for Reconstruction and Development on an extension of the company's credit facility (revolving credit facility) of the total value of EUR 19.8m and PLN 20mn to January 31, 2021 interest rate and other provisions remain unchanged.The extension allows the company to complete an ongoing process that aims to simplify the debt structure, further optimize the conditions and reduce the costs of debt service.

Västra Hamnen: ViroGates - Stronger across the board

Västra Hamnen Corporate Finance has published a research update on ViroGates following its report for the third quarter 2020. The numbers were uniformly better than expected, but not enough to change our valuation, writes Västra Hamnen.· Revenues higher and costs lower than expected · Two new clinical routine customers in the quarter · Given the uncertainty, we retain valuation range of DKK 68.00 – 100.50 per share In this morning’s Q3 report from ViroGates, the figures were almost uniformly better than we had expected. Net revenues were a full 70 percent higher than our estimate.

Episealer® publication available online

Episurf Medical (Nasdaq: EPIS B) today communicates that a publication with the title “Successful Treatment of Femoral Chondral Lesions with a Novel Customized Metal Implant at Midterm Follow-Up” from a Swedish prospective multicentre study has been published in the scientific journal Cartilage. In total, 30 Episealer® patients are included in the study and the average follow-up time is 55 months (subjective outcome scores at 24 months, survival data at 24 – 86 months, mean of 55 months). The authors conclude the study with the words “The risk of OA progression and implant loosening is

CDON AB's shares will be admitted to trading on Nasdaq First North Growth Market

Press release, Stockholm, 27 October 2020CDON AB ("CDON") today publishes a company description prior to the admission to trading of CDON's shares on Nasdaq First North Growth Market. CDON has received a conditional approval for listing and the first day of trading will be Friday, 6 November 2020. The admission to trading is part of the distribution of all of Qliro Group AB's (publ) (“Qliro Group”) shares in CDON to the holders of ordinary shares in Qliro Group, which was resolved at an Extraordinary General Meeting of Qliro Group on 26 October 2020. CDON's company description will be

Agreement for liquidity providing terminated

Press release: Uppsala, October 27, 2020. The agreement with Mangold Fondkommission to act as the liquidity provider for Dicot AB’s share has been terminated. The assignment will end on October 29, 2020. The share has a good spread and the liquidity providing is no longer needed. No new liquidity guarantor replaces the previous commitment as the need no longer exists.If you have additional questions, please contact: Göran Beijer, CEO Tel: +46 70-663 60 09 E-mail: goran.beijer@dicot.se   Dicot AB in brief Dicot is a pharmaceutical company focused on drug discovery and the

#20-383 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies wishing to

WindowMaster International A/S: Notification of transactions by persons discharging managerial responsibilities and persons closely associated with them

Company Announcement No. 5 -2020 Copenhagen, October 27[th], 2020 In accordance with the Market Abuse Regulation, WindowMaster International A/S must notify Finanstilsynet and publicly disclose transactions made by persons discharging managerial responsibilities and persons closely associated with them on trading of WindowMaster International A/S shares. WindowMaster International A/S hereby notify and submit the following transaction of shares in WindowMaster International A/S: Name:                                    Lars Fournais Title:

Nomination Committee of Scandi Standard for the annual general meeting 2021

The nomination committee for Scandi Standard AB’s (publ) annual general meeting 2021 consists of the following members: · Andreas Hofmann (chairman, appointed by Investment AB Öresund); · Justin Carton (appointed by Carton Shareholders); · Johannes Wingborg (appointed by Länsförsäkringar Fondförvaltning AB); · Per Olof Nyman (appointed by Lantmännen); and · Per Harkjaer (chairman of the board of directors of Scandi Standard). The nomination committee is to prepare and make proposals to the annual general meeting 2021 regarding: · elections of the chairman of the

Invitation to presentation of Multiconsult ASA’s third quarter and Capital Markets Day

Multiconsult ASA's third quarter 2020 results will be released on Wednesday 4 November at 07:00 CET. A presentation of the results followed by Capital Markets Day will be held at Felix Conference Centre, Bryggetorget 3, Oslo at 08:30 CET. The complete report and presentation will be available at www.multiconsult-ir.com and www.newsweb.no.Program · 08:15                Registration · 08:30 - 09:00     Third quarter 2020 presentation · 09:15 - 11:30     Capital Markets Day Light lunch will be served at 11:30 The presentations will be held in English by CEO Grethe Bergly and

Gaming Innovation Group: Invitation to Q3 2020 results presentation

Gaming Innovation Group Inc. (GiG) publishes its interim report for the third quarter 2020 before market opening on Wednesday 4 November 2020. CEO Richard Brown will present the Q3 2020 results via livestream at 10:00 CET. The presentation will be followed by a Q&A-session, and investors, analysts and journalists are welcome to participate. The presentation will be given in English. Link to the livestream: https://www.redeye.se/events/796108/gaming-innovation-group-liveq-presentation-and-qaFor further information, please contact:Tore Formo, Group CFO, tore@gig.com, +47 91668678

Immunovia Provides Complementary Information on the IMMray[™] PanCan-d Verification and Validation Studies

LUND, SWEDEN – Immunovia, a diagnostic company that develops highly accurate blood tests for the early detection of cancer and autoimmune diseases, today announced a necessary clarification to supplement the information shared on 26 October 2020 (link to press release ). About Blood Sample Inclusion Criteria It is standard practice to have specific inclusion criteria in place for the collection of blood samples for all diagnostic studies. Immunovia has always

There are no items matching the current filter
There are no more items matching the current filter
Back to top